<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830231</url>
  </required_header>
  <id_info>
    <org_study_id>Secavin-12</org_study_id>
    <nct_id>NCT01830231</nct_id>
  </id_info>
  <brief_title>Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)</brief_title>
  <official_title>A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associació per a la Recerca Oncologica, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associació per a la Recerca Oncologica, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to limited experience with cabazitaxel in TCCU, the study will be started as a randomised
      phase II study. The aim of the phase II study is to evaluate if the response rates (CR + PR)
      are sufficiently high to further study the treatment regimens in a phase III setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the
      informed consent, they will be randomised to receive treatment based on cabazitaxel or
      vinflunine according to the following study schema:

      (Randomize 1:1)

        -  Cabazitaxel 25 mg/m2 q3w

        -  Vinflunine 250-320 mg/m2 q3w

      Random assignment of treatment will be stratified by the presence of 0 versus 1 of the
      following unfavourable prognostic risk factors proposed recently by Bellmunt et al. (1):

        -  Eastern Cooperative Oncology Group (ECOG) PS 1.

        -  Anaemia with Hb &lt;10 g/dL.

        -  Presence of liver metastases.

      All patients enrolled in the study will receive a cycle of treatment with the study
      medication (cabazitaxel or vinflunine) every 21 days until disease progression or
      intolerable/unacceptable toxicity. Tumour evaluations will be scheduled every 6 weeks until
      progression
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II main objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objective response rate (ORR) of subjects with metastatic or locally advanced previously treated TCCU.</measure>
    <time_frame>From date of randomization to disease progression or until 18 months from enrolment.</time_frame>
    <description>Efficacy of cabazitaxel compared to vinflunine on terms of improved objective response rate (ORR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III main objective: To assess the efficacy of cabazitaxel compared to vinflunine in terms of improved overall survival (OS) of subjects with metastatic or locally advanced, previously treated TCCU.</measure>
    <time_frame>From date of randomization to death from any cause or until 18 months from enrolment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved progression-free survival (PFS) and overall survival (OS).</measure>
    <time_frame>From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.</measure>
    <time_frame>From the date the informed consent is signed up to 30 days after the last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objetive response rate (ORR) and progression free survival (PFS).</measure>
    <time_frame>From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.</measure>
    <time_frame>From the date the informed consent is signed up to 30 days after the last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Urothelium Transitional Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinflunine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Vinflunine will be given intravenously once every 21 days, starting at a dose of:
320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation
280 mg/m2 in patients aged &gt;75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,
250 mg/m2 in patients aged &gt;80 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <description>Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:
320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of
280 mg/m2 in patients aged &gt;75 - ≤80 years or with PS 1 or prior pelvic radiation,
250 mg/m2 in patients aged &gt;80 years.</description>
    <arm_group_label>Vinflunine</arm_group_label>
    <other_name>Javlor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically confirmed TCCU (urinary bladder, urethra, ureter or renal pelvis).
             Patients with mixed histology may be enrolled if TCCU is the predominant component
             (i.e., &gt; 50% of the histopathology sample) with the exception of neuroendocrine or
             small cell carcinoma.

          -  Advanced disease defined as a locally advanced tumour considered unresectable (T4b),
             node involvement in the inguinal area or above the aortic bifurcation (that are
             considered to be distant nodes and so metastasis) or metastasis in distant organs.

          -  Patient should have received one prior platinum-based chemotherapy treatment for
             locally advanced or stage IV TCCU. Prior platinum-based adjuvant or neoadjuvant
             therapy is allowed if more than 6 months have elapsed since the end of adjuvant or
             neoadjuvant therapy till tumour relapse.

          -  At least one measurable tumour lesion (measurable disease, as defined by the Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1

          -  ≥18 years.

          -  ECOG PS 0 or 1.

          -  May have no more than ONE of the following unfavourable risk factors:

               1. haemoglobin &lt;10 g/dL

               2. presence of liver metastasis

               3. ECOG PS 1

          -  Life expectancy of at least 12 weeks.

          -  Adequate hematologic, hepatic, and renal function, defined by:

          -  Females of childbearing potential must have a negative serum pregnancy test within 7
             days of study entry.

        Exclusion Criteria:

          -  Patients that have 2 or more of the following unfavourable risk factors:

               1. Haemoglobin &lt;10 g/L

               2. Liver metastasis

               3. ECOG PS 1.

          -  Women who are currently pregnant or breast-feeding.

          -  Any unresolved non-hematologic Adverse Event (AE) grade &gt;1 (Common Toxicity Criteria
             for Adverse Effects (NCI-CTCAE) Version 4.0) from previous anti-cancer therapy (other
             than alopecia)

          -  Patients who had undergone major surgery, radiation therapy or treatment with
             chemotherapy or any investigational agent within 28 days prior to Study day 1.

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition

          -  History of another neoplasm.

          -  History of hypersensitivity reactions to taxanes (docetaxel) (cabazitaxel specific
             criteria), vinca alkaloids (vinflunine specific criteria) or to any of the formulation
             excipients, including polysorbate 80

          -  clear evidence or symptoms of central nervous system metastasis (cabazitaxel specific
             criteria).

          -  Clinically significant cardiac condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APRO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    <phone>+34 93 2483137</phone>
    <email>jbellmunt@parcdesalutmar.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inmaculada Musté</last_name>
    <phone>+34 93 2483137</phone>
    <email>oncologia.apro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NKI-AvL</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martijn Kerst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vumc Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>van den Eertwegh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antoniusziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maartje Los, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronald De witt, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Urbano Anido</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Federico J. Vázquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose L. Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Miguel Antón Aparicio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galica</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquim Bellmunt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>93 274 61 00</phone>
    </contact>
    <investigator>
      <last_name>Rafael Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo Collado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gustavo Rubio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Luis González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Castellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Ourense. Hospital Santa María Nai</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ovidio Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Belén González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lzoano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Pujol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10;28(11):1850-5. doi: 10.1200/JCO.2009.25.4599. Epub 2010 Mar 15.</citation>
    <PMID>20231682</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TCCU</keyword>
  <keyword>Vinflunine</keyword>
  <keyword>Cabazitaxel</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Locally advance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

